The bottom line up front
KNSC11 is a Brazilian REIT (FII — Fundo de Investimento Imobiliário) that invests exclusively in real estate credit instruments (CRIs — Certificados de Recebíveis Imobiliários), similar to mortgage-backed securities. On July 24, 2026, Kinea — the fund's manager and an arm of Itaú, Brazil's largest private bank — approved a 6th equity raise. As a current holder, the core question is simple: subscribe at R$8.95 or take the dilution? Subscribe if you have dry powder — you lock in a 1.6% discount to market price and avoid dilution. But don't mistake the book-value figure (R$8.70) for the actual cost: the 2.87% distribution fee eats most of that apparent discount. And brace for a slightly softer distribution for a month or two while the new cash gets deployed into CRIs.
What was approved
Kinea and Intrag (the fund's administrator) approved the 6th equity offering of KNSC11 — Kinea Securities CRI FII on July 24, 2026. This is Kinea's flagship CRI fund: 89 real estate credit instruments, R$1.76 billion in assets under management, and 283,875 individual holders. The raise targets 45,977,012 new units at base, with a 25% greenshoe that can push the total to 57,471,265 units and R$500 million. The offering is structured as best-efforts (no underwriting guarantee), coordinated by XP Investimentos. It only needs to close R$30M to avoid cancellation. All proceeds go toward new CRIs within the same investment mandate — no strategy change.
How preemptive rights work here
Brazilian equity offerings for listed FIIs must give current holders the right to subscribe before new investors can participate. The rights ratio of 0.22738 defines how many new units each existing unit entitles you to. For every 1,000 units you hold at the record date, you may subscribe approximately 227 new units (1,000 × 0.22738 = 227.38). If you hold 5,000 units, that's ~1,137 new units available to you.
Beyond the base allocation, there's also an oversubscription right: if you exercise your full preemptive rights, you can request additional units that other holders left unclaimed. This is the route for anyone wanting to increase their position at the offering price rather than paying market price.
Rights only become exercisable after the Announcement of Commencement of the offering — which hasn't been published yet as of this article. When it drops, the rights typically trade on the exchange under a separate ticker (often the fund ticker + 2). They expire quickly. If you do nothing and the rights expire worthless, you receive no compensation for the dilution you absorb.
The real math: R$8.95 vs R$9.10
The offering headline says R$8.70 per unit — book value as of June 30, 2026. But you don't actually pay R$8.70. There's a 2.87% distribution fee — R$0.25/unit — built into the subscription price, bringing the actual cost to R$8.95.
| Reference | Price/unit | vs. Market (R$9.10) |
|---|---|---|
| Book value (Jun 30) | R$8.70 | −4.4% (not what you pay) |
| Subscription price (all-in) | R$8.95 | −1.6% (real discount) |
| Secondary market | R$9.10 | reference |
The true discount against buying on the open market is R$0.15/unit (1.6%) — not the 4.4% the NAV number implies. The distribution fee absorbs more than half of the apparent discount. You're still buying below market, which is the point of a rights offering, but it's a thin margin that a small secondary-market move can erase before settlement.
How quickly does the math recover? The fund's monthly distribution (DPS — Distribuição Por Cota) currently runs around R$0.097. The R$0.15 discount equals roughly 1.5 months of distributions. Given that the portfolio yields IPCA+10.31% on 61% of assets and CDI+3.14% on the remaining 38% (CDI being Brazil's interbank overnight rate, currently ~14.5%), the subscription cost is recovered in a matter of months — assuming the new cash gets deployed promptly.
The dilution scenario for non-subscribers
Sitting out isn't neutral. Because new units are issued at R$8.70 — below the R$9.10 market price — holders who don't subscribe get diluted by units priced at a discount. In the maximum scenario (R$500M raise), the unit count grows by roughly 28%. Your percentage ownership of the fund's income and assets shrinks proportionally.
Three paths available: (1) subscribe and maintain or grow your stake; (2) sell your rights on the secondary market, capturing part of their economic value; or (3) do nothing — the worst outcome, as you absorb the dilution without any compensation.
How Kinea deploys capital
The R$400–500M will go into new CRIs under the same investment policy: mid-yield real estate credit, mix of IPCA-linked (inflation-indexed) and CDI-linked instruments, Kinea's origination desk. Kinea has a clean track record on deployment speed compared to smaller CRI managers — the firm typically avoids prolonged cash drag. The current portfolio benchmarks (IPCA+10.31% / CDI+3.14%, WAULT of 5.8 years) set the floor for new CRIs.
The one near-term effect to expect: while fresh cash sits idle waiting to be deployed into CRIs, it earns only CDI returns via short-term repo agreements — below the portfolio's blended yield. This will likely mute distributions for one or two months post-settlement. That's normal mechanics for any equity raise, not a fund-specific concern.
Where the fund stands today
Context matters. Over the past ten months, KNSC11's monthly distribution fell roughly 33% — from R$0.12 in April 2025 to R$0.08 in February 2026 — driven by lower IPCA (Brazil's consumer price index, which ties 61% of the portfolio's income) and a declining Selic rate compressing CDI-linked returns. By June 2026, the distribution recovered to R$0.10, and the fund still carries a reserve buffer of ~R$0.05/unit. Trailing 12-month yield: 12.5%.
Risks the offering doesn't fix: 24.5% exposure to office CRIs (elevated vacancy in São Paulo and Rio de Janeiro AAA buildings); ~7% aggregate exposure to the Brookfield BR12 portfolio across 8 separate CRIs (Senior and Junior tranches); repo leverage at ~10.6% of AUM, above Kinea peers; and residual provisioning on two retail-sector CRIs (Casa&Video and Le Biscuit, equivalent to 1.2% of AUM, already absorbed by reserves). Silver lining: R$400–500M in new CRIs will dilute these concentrations rather than amplify them — provided Kinea doesn't double down on the same sectors.
What to do with KNSC11's 6th offering
If you hold KNSC11 and have capital available, subscribe: you buy 1.6% below market and prevent dilution. The discount is thin because of the 2.87% distribution fee, but the portfolio's blended yield (IPCA+10.31% / CDI+3.14%) makes up the difference within a few months, and Kinea has a credible track record of deploying capital without sitting on cash for quarters. If you don't want to add exposure, sell the rights rather than letting them expire. Expect one or two softer distribution months after settlement as new CRIs are onboarded — that's the mechanics, not a warning sign. Doing nothing remains the only clearly bad choice.
